Trial Profile
Evaluation of utilization, safety and tolerability of ocrelizumab in patients with multiple sclerosis: Providence Ocrelizumab Registry
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 25 Oct 2018 New trial record
- 12 Oct 2018 Results (n=223) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.